Pictet Asset Management
CPRX

Pictet Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Pictet Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$532K Sell
16,914
-2,899
-15% -$85.6K ﹤0.01% 1472
2026
Q1 		$491K Buy
19,813
+39
+0.2% +$929 ﹤0.01% 1467
2025
Q4 		$462K Buy
19,774
+2,148
+12% +$47.8K ﹤0.01% 1486
2025
Q3 		$347K Hold
17,626
– – ﹤0.01% 1568
2025
Q2 		$382K Buy
17,626
+1,657
+10% +$39.1K ﹤0.01% 1501
2025
Q1 		$387K Hold
15,969
– – ﹤0.01% 1476
2024
Q4 		$333K Buy
15,969
+3,431
+27% +$73.7K ﹤0.01% 1588
2024
Q3 		$249K Hold
12,538
– – ﹤0.01% 1706
2024
Q2 		$194K Hold
12,538
– – ﹤0.01% 1771
2024
Q1 		$200K Hold
12,538
– – ﹤0.01% 1771
2023
Q4 		$211K Hold
12,538
– – ﹤0.01% 1722
2023
Q3 		$147K Buy
+12,538
New +$168K ﹤0.01% 1759

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pictet Asset Management's CPRX Position: Q2 2026 in Review

Pictet Asset Management reduced its Catalyst Pharmaceutical (CPRX) stake by 15% in Q2 2026, selling an estimated $85.6K and leaving 16,914 shares worth $532K. The position accounts for ﹤0.01% of the portfolio, ranked #1472.

Pictet Asset Management first reported a position in CPRX in Q3 2023 and has held it in 12 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Pictet Asset Management held 16,914 shares of Catalyst Pharmaceutical worth $532K as of Q2 2026.
  • Pictet Asset Management sold 2,899 Catalyst Pharmaceutical shares in Q2 2026, an estimated $85.6K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #1472 holding.
  • Pictet Asset Management first reported a position in Catalyst Pharmaceutical in Q3 2023 and has held it in 12 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.